Dmytriy G. Kesarev
Dmytriy G. Kesarev has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anna A. Gamaleya
N. N. Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia
2 shared publications - Anna A. Poddubskaya
N.N. Burdenko National Medical Research Center of Neurosurgery
2 shared publications - Ekaterina V. Bril
State Scientific Centre of the Russian Federation – Federal Medical Biophysical Centre n. a. A. I. Burnazyan; Russian Medical Academy of Continuous Professional Education
2 shared publications - Natalia V. Fedorova
Russian Medical Academy of Continuous Professional Education
2 shared publications - Аleksey A. Tomskiy
N.N. Burdenko National Medcial Research Center of Neurosurgery Moscow Russia
2 shared publications - Oleg S. Levin
Russian Medical Academy of Continuous Professional Education
1 shared publication
Latest Publications
- 6 March 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (2) , 21-27
Pathomorphosis of the Parkinson’s disease against the background of DBS STN
Objectives. To study the clinical pathomorphosis of Parkinson’s disease (PD) against the background of stimulation of the subthalamic nucleus (DBS STN). Material and methods: We present a 15-year analysis of 401 patients with PD in two groups: DBS STN (n=233) and drug therapy group (n=168). In order to study the clinical pathomorphism of the disease, an analysis of the dynamics of the main motor symptoms of PD was carried out using the UPDRS scale, as well as an analysis of the survival of patients in both groups. Results. DBS STN significantly improved motor symptoms in patients with PD during the off period by 57.3% by year 1, by 23.7% by year 15. According to this indicator, patients did not reach the preoperative level. During the inclusion period in this group, the improvement was 40%, the indicator remained stable for 3 years, however, due to the progression of the disease, by the 15th year the deterioration was 20.9%. In the group of patients receiving only drug therapy, there was a progressive worsening of motor symptoms in the off period by 67.5% by the 15th year of observation, in the on period 64.5% (p<0.05). Univariate survival analysis showed that patients receiving STN—DBS had significantly longer survival than those receiving medical treatment alone (p=0.008). Conclusion. DBS STN changes the clinical pathomorphosis of Parkinson’s disease, leading to less severity of parkinsonian symptoms and greater survival of this group of patients.
- 6 March 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (2) , 21-27
Pathomorphosis of the Parkinson’s disease against the background of DBS STN
Objectives. To study the clinical pathomorphosis of Parkinson’s disease (PD) against the background of stimulation of the subthalamic nucleus (DBS STN). Material and methods: We present a 15-year analysis of 401 patients with PD in two groups: DBS STN (n=233) and drug therapy group (n=168). In order to study the clinical pathomorphism of the disease, an analysis of the dynamics of the main motor symptoms of PD was carried out using the UPDRS scale, as well as an analysis of the survival of patients in both groups. Results. DBS STN significantly improved motor symptoms in patients with PD during the off period by 57.3% by year 1, by 23.7% by year 15. According to this indicator, patients did not reach the preoperative level. During the inclusion period in this group, the improvement was 40%, the indicator remained stable for 3 years, however, due to the progression of the disease, by the 15th year the deterioration was 20.9%. In the group of patients receiving only drug therapy, there was a progressive worsening of motor symptoms in the off period by 67.5% by the 15th year of observation, in the on period 64.5% (p<0.05). Univariate survival analysis showed that patients receiving STN—DBS had significantly longer survival than those receiving medical treatment alone (p=0.008). Conclusion. DBS STN changes the clinical pathomorphosis of Parkinson’s disease, leading to less severity of parkinsonian symptoms and greater survival of this group of patients.
- Open Access
- 3 October 2024
- Published by ECO-Vector LLC in Annals of Clinical and Experimental Neurology
- Vol. 18 (3) , 91-102
Deep Brain Stimulation Withdrawal Syndrome, a Rare Life-Threatening Condition in Neurology and Neurosurgery
The article addresses an acute condition associated with an abrupt cessation of neurostimulation of deep brain structures, which is manifested by acute hypokinesia and rigidity with further development of akinesia, anarthria and dysphagia. This may result in the need for emergency hospitalization and admission to an intensive care unit. The article presents literature review and clinical case reports. We discuss causes and approaches to the prevention and management of acute decompensation in patients with Parkinson's disease associated with abrupt deep brain stimulation cessation.
- 3 October 2024
- Published by ECO-Vector LLC in Annals of Clinical and Experimental Neurology
- Vol. 18 (3) , 91-102
Open AccessDeep Brain Stimulation Withdrawal Syndrome, a Rare Life-Threatening Condition in Neurology and Neurosurgery
The article addresses an acute condition associated with an abrupt cessation of neurostimulation of deep brain structures, which is manifested by acute hypokinesia and rigidity with further development of akinesia, anarthria and dysphagia. This may result in the need for emergency hospitalization and admission to an intensive care unit. The article presents literature review and clinical case reports. We discuss causes and approaches to the prevention and management of acute decompensation in patients with Parkinson's disease associated with abrupt deep brain stimulation cessation.